Shareholders’ Agreements 101 – FAQs about a key agreement

By Faith Sing Spinning out a biotech company from a university, research institute or hospital is likely to involve different decisions to that scientists are used to making. It is likely to first involve fundamental “go or no go” issues such as ensuring that the invention has a future as a business, refining the business model and developing a more granular business plan. If there is a potentially viable business model, you may be looking to enter into collaborations and raise funds to grow and operate the business. In addition, you may need to take a number of “legal related” steps which are also important to develop the business, such as: setting up the company and putting in place arrangements for its smooth running, entering into a license agreement or an assignment of the intellectual property rights that protect the technology, and setting up various agreements with stakeholders and collaborators to take the next steps in the development of the technology.…

Singapore FinTech Festival (SFF) x SWITCH is coming on 7-11 December!

Biotech Connection Singapore (BCS) partners with Singapore Week of Innovation and TeCHnology (SWITCH), the leading tech festival for the Global-Asia innovation ecosystem. Together with the Singapore FinTech Festival, SFF x SWITCH will take place on 7-11 December 2020—get ready for an exciting week-long, round-the-clock, digital and physical event! You can expect a world-class technology and innovation conference featuring deep dives into sectors like healthcare & biomedical sciences, smart cities & urban solutions, trade & connectivity and emerging technologies, with a focus on people and talent. Get access to curated networking and business matching functions, and participate in workshops and masterclasses throughout the week. Asia’s most anticipated startup pitching competition, SLINGSHOT, and TechInnovation, the premier technology-industry brokerage event will also be taking place at SWITCH. Don’t miss this!

What is an alliance manager?

Companies are always on the lookout for interesting new technologies that can value-add their business. Who scouts for these breakthroughs? Introducing - the alliance manager. Contributed by: Zheng-Shan Chong and Shweta Jadhav

What does it take for an investor to say YES?

by Shainan Hora From 2015-2020, a total of 70 deals were made locally in the Singapore biotech and healthcare sector. Out of the companies founded in the last five years, US$93M was raised by AI-based medical diagnostics and digital health start-ups, and US$105M by start-ups working on immunotherapy and drug-based therapeutics (based on disclosed funding information only). So, what constitutes a good investment? What aspects are looked at before investing? BCS spoke to Dr. Jessie Tong, Senior Manager at SGInnovate Venture Investing team and Dr. Koh Fong Ming, Senior Associate at Heritas Capital Management, to get their insights on the investment landscape in Singapore. A good founder There isn’t a simple checklist for this one as the requirements vary based on the specific industry sub-sector and the growth and developmental stage of the company. However, there are a few things that investors are drawn to: Who you are: It goes without saying that entrepreneurs must be mentally…

Regulatory Affairs Webinar Series: Post-event writeup

Regulations are made by the government to protect public health by ensuring the safety and efficacy of medicines, vaccines, and medical devices. Based on regional and economic constraints, the regulatory bodies around the globe differ in their guidelines, making it challenging even for regulatory affairs professionals to navigate. To aid in the understanding of these variations, BCS recently organised a three-part webinar-based workshop series on regulatory affairs, given by experts in different domains of regulation in Asia, Europe, and America.

What on earth is a technical writer?

In this series we explore the day-to-day lives of researchers who have successfully transitioned to various non-academic roles. First up - Technical writing! Contributed by: Zheng-Shan Chong

Scientific Advances in Times of COVID-19: Post-event write-up

As part of COVID-19 webinar series, Biotech Connection Singapore (BCS) hosted speakers from academic and industry settings to discuss advances in the research community under the new ‘norm’, as well as the research efforts undertaken in facilitating basic and translational research in the fight against SARS-COV-2. The panel included:  Dr. Ooi Eng Eong, Professor and Deputy Director of the Emerging Infectious Diseases Programme at Duke-NUS Medical School  Mr. Rajeev Nair, Senior VP and Head of APAC Research Solutions, Life Science, Merck  Mr. Mark Dupal, APAC Senior Sales Director of Twist Bioscience